StreetAlpha.app
Home › Stocks › LRMR

Larimar Therapeutics, Inc. (LRMR)

Healthcare
$2.99
▼ −0.33%
LAST CLOSE · NOV 17

Larimar Therapeutics develops treatments for rare diseases, starting with a drug candidate for Friedreich's ataxia that uses its cell penetrating peptide platform. It last closed at $2.99 on Nov 17, down 0.33% on the day. The average 12-month price target from 2 analysts is $11.00 (+267.9% from the last close), with a high of $13.00 and a low of $9.00. In the past 30 days there were 3 dark pool prints totaling $382K, the largest $143K.

AI Auto Pilots
Is LRMR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$156.0M
Free cash flow
−$158.5M
Valuation
Market cap
$312.9M
104.6M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$77.0M
At Sep 30
Shareholder equity
$101.5M
Shares outstanding
104.6M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$50.6M−$50.6MFY2021FY2022: −$35.4M−$35.4MFY2022FY2023: −$36.9M−$36.9MFY2023FY2024: −$80.6M−$80.6MFY2024FY2025: −$165.7M−$165.7MFY2025

From LRMR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated LRMR in the past 90 days, not enough for a consensus
Average 12-month target
$11.00
▲ 267.9% upside

Based on 2 analysts who set a price target on LRMR in the past 90 days. The average target is $11.00, with a high of $13.00 and a low of $9.00, compared with the last close of $2.99.

Low $9.00Avg $11.00High $13.00
Blue marker: last close $2.99
Highest target$13.00
Average target$11.00
Lowest target$9.00
Latest rating changes
WedbushMaintained
Nov 17Buy$9
Leerink PartnersAssumed coverage
Sep 14Buy$13
HC Wainwright & Co.Assumed coverage
Jul 2Buy$10
BairdMaintained
Jun 30Buy$5
JP MorganInitiated
May 27Buy$9
DateFirmActionRatingPrice target
Nov 17WedbushMaintainedBuy$9
Sep 14Leerink PartnersAssumed coverageBuy$13
Jul 2HC Wainwright & Co.Assumed coverageBuy$10
Jun 30BairdMaintainedBuy$5
May 27JP MorganInitiatedBuy$9
Loading…

Technical Analysis

LRMR · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock is 14% above its 20 day and 3% above its 50 day average. It is 26% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 59). The nearest support is the swing low (Jun 29) at $2.92, and the nearest resistance the Pivot at $3.01.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityHigh, 8.5%/day
Key levels
$6.4252 week high+114.7%
$3.76200 day average+25.8%
$3.67Swing high (May 27)+22.7%
$3.40100 day average+13.7%
$3.11Pivot R1+4.0%
$3.01Pivot+0.7%
$2.99Last close
$2.92Swing low (Jun 29)−2.3%
$2.9050 day average−3.0%
$2.88Pivot S1−3.7%
$2.5720 day average−14.0%
$1.9252 week low−35.8%
Indicators
RSI (14)58.61Middle of its rangeNeutral
MACD0.04Above its signal lineBullish
Stochastic78.7Middle of its rangeNeutral
ADX (14)23.1Weak trend
Williams %R-29.3Oversold below −80, overbought above −20Neutral
CCI (20)157.7Oversold below −100, overbought above 100Overbought
Rate of change+17.7%Change over 10 sessionsBullish
ATR (14)$0.26Typical daily range, 8.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for LRMR

What happened before

See how LRMR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow LRMR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LRMR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in LRMR in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$382K
Largest print
$143K
Loading…

LRMR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼59 buying vs 86 selling
  • ▲Held by funds +8.4 pts
  • ▼Funds holding -17
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding146163−10.4%
In funds' top 10110.0%
Held by funds99.6%91.2%+8.4 pts
New / increased12 / 4732 / 68−41.0%
Reduced / sold out56 / 3041 / 30+21.1%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LRMR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LRMR is in one of them and how their past LRMR trades turned out.

LRMR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LRMR in an article yet. Here's the latest on the wider market.

About Larimar Therapeutics

Larimar Therapeutics is a biotechnology company based in Bala Cynwyd, Pennsylvania, that develops treatments for complex rare diseases. Its lead candidate, nomlabofusp, is a drug given by injection under the skin that is designed to deliver frataxin, a protein the body needs, to patients with Friedreich's ataxia. The company uses its cell penetrating peptide platform, which helps therapeutic molecules cross cell membranes, and it aims to apply that platform to other rare diseases. The drug is still in clinical development and is not yet approved for sale.

Headquarters
Bala Cynwyd, PA
Founded
2005